We are a gene therapy company for developing safe gene medicines and potent transfection reagents.
HPAEs platform technology
Toward Next Generation of High-Performance Non-Viral Gene Delivery Vectors
Our new website is under construction. Any inquries please contact [email protected]. Thanks for your understanding!
Our new address: Lab 4, Building 10, Cherrywood Business Park, Cherrywood, Loughlinstown, Co. Dublin, lreland, D18 T3Y1
Abous Us
“Empowering Breakthroughs in Biotech with High-Efficiency and Cost-Effective Transfection Reagents”
At Branca Bunus Ltd, we provide researchers, CDMOs, biotech and pharm companies with high-performance transfection reagents that deliver unmatched efficiency, scalability, and reliability. Our innovative solutions are designed to streamline viral vector transient production in cell and gene therapy, and protein transient production workflows, enabling faster and more cost-effective breakthroughs in life sciences.
Why Choose Us?
- Dedicated Support: Our team provides expert technical support and training to ensure your success every step of the way.
- Superior Performance: Our transfection reagents achieve higher efficiency and cell viability than traditional options, ensuring optimal results for even the most challenging applications.
- Scalability: From small academic labs to large-scale CDMO production, our reagents are designed to scale seamlessly with your needs by easy preparation and super stable transfection complex.
- Cost-Effectiveness: We offer premium quality at competitive prices, helping you reduce costs while achieving multiple times in the performance.
- Custom Solutions: Tailored designs and formulations to meet the unique demands for targeted delivery of pDNA, siRNA, mRNA and CRISPR complex in vitro and in vivo.
- Trusted by Industry Leaders: Already adopted by top CDMOs and Biotech, our reagents are proven in real-world, high-stakes environments.
News
Branca Bunús and Duoning Biotech Celebrate Strategic Partnership During Irish Ministerial Visit to Shanghai
Shanghai, March 14, 2025 – In the spirit of celebrating St. Patrick’s Day and fostering Irish-Chinese collaboration, Branca Bunús Ltd and Duoning Biotech convened a pivotal meeting in Shanghai on March 14th. The event took place ahead of Ireland’s national holiday and was held in the presence of a high-level Irish government delegation, including Minister for Housing, Local Government and Heritage, James Browne TD, Ireland’s Ambassador to China, Dr Nicholas O’Brien, Consul General of Ireland in Shanghai, David Murphy, and Pat O’Riordan, Director China of Enterprise Ireland.
This important gathering marked a significant milestone in the strategic partnership between Branca Bunús and Duoning Biotech, following their collaboration announcement in November 2024. The partnership focuses on the co-development and commercialization of the BrPERfect® next-generation transfection reagents, aimed at providing innovative, high-performance gene delivery solutions for biopharmaceutical companies in China and beyond. For full press release please check out the links below:
Duoning Biotech announced strategic partnership with Branca Bunús to promote the next generation of transfection reagents
Duoning Biotechnology Group announced a strategic partnership agreement with Branca Bunús Ltd. Under this agreement, the two companies will collaborate on the development, optimization, and application of transfection reagents, with the goal of providing biopharmaceutical customers with innovative transfection reagents through resource sharing, thereby enhancing the efficiency of biopharmaceutical development in upstream bioprocess. For full press release please check out the links below:
Full Press Release for Download
Press Release on PRNewswire
Branca Bunús gained Type II DMF ID from FDA for its BrPERfect transfection reagent!
Branca Bunús has reached another milestone with successful submission of a Drug Master File (DMF) to FDA, for its lead product, HPAE polymer-based transfection reagent. We were pleased to receive the certificate confirming Branca Bunús Ltd as a DMF holder (DMF number 39924) from June 2024.
For Biotech and pharmaceutical companies, submitting a DMF to FDA is an important step that demonstrates commitment to quality and will facilitate regulatory approval and compliance. DMFs provide details on how a substance is manufactured and processed to confirm that it meets strict regulatory standards. Various types of DMFs are in use, in this case Type II which is relevant for pharmaceutical manufacturing.
Good news from Branca Bunús Ltd!
We have achieved certification from the National Standards Authority of Ireland (NSAI) that our Quality Management System meets the requirements of international standard ISO 9001:2015.
Left to right: Prof Wenxin Wang, Dr Xianqing Wang, Dr Irene Lara-Sáez, Dr Hongyun Tai, Dr Ruth Foley, Dr Xi Wang, Dr Melissa Johnson, Irene Reuben, Liang Yao. Inset: Dr Zhonglei He, Jianming Sun.
“Gaining the NSAI certification is a significant achievement of the company as we regard our global customers as the centre of our business and our core mission is to provide high quality products and services to our customers.”
Dr Hongyun Tai, Managing Director and CEO
IS0 9001:2015 is the international standard for the most recognised quality management system worldwide and sets out standardised requirements across a wide range of industries. The QMS maintained in Branca Bunús covers the company’s processes, procedures, and responsibilities in developing and manufacturing our products including gene transfection reagent BrPERfect series. The benefits of implementing this QMS allow Branca Bunús to establish confidence in ensuring compliance with regulatory requirements and with the key focus of meeting customer needs for the quality of the products and services.